About Glionova

About company

Glionova AB, a development stage biopharmaceutical company, is engaged in the development of therapies for difficult-to-treat cancers. The company develops GLN-1001, an orally bioavailable small molecule that induces selective cell death in glioblastoma cells without causing harm to normal brain tissue.